Search

"Objective To investigate the application of in-hospital informatized blood glucose monitoring system (IGMS) in Jiangsu and the satisfaction of medical staff to use IGMS. Methods From August 2021 to July 2022, a survey was conducted among medical staff in 119 secondary and tertiary hospitals in Jiangsu Province. The survey included questions on the application status of IGMS, such as the year of initiation and the medical units using it, and the satisfaction with the use of IGMS in medical staff was investigated by a 5-level Likert scale. Results (1) Utilization rate of IGMS: among the 119 hospitals, 58 (48.7%) utilized IGMS. The utilization rate in Southern Jiangsu (61.0%) was significantly higher than that in Central Jiangsu (34.8%) and Northern Jiangsu (37.8%) (χ2=7.113,P=0.029). (2) Distribution of medical units using IGMS: utilization rate in internal medicine department (96.6%) was significantly higher than that in surgical department (51.7%) and ICU (39.7%) (χ2=44.550,P＜0.01), with the highest utilization rate observed in endocrinology department (96.6%). (3) Satisfaction survey: the satisfaction scale had a Cronbach's alpha of 0.702 and a KMO value of 0.742, and Bartlett's sphericity test yielded aχ2 value of 298.268 (P＜0.01). Two initial factors with eigenvalues greater than 1 accounted for 72.5% of the variance. Following a scree plot analysis, two factors were extracted ,and the items were deleted according to the reliability and validity, and the satisfaction scale containing two factors and seven items was finally determined. Ninety-seven medical staff completed the scale with a score of 29.0 (25.5, 31.0). There was no significant difference in personal satisfaction with IGMS among medical staff in different regions, hospitals of grades and titles (P＞0.05). Conclusion The utilization rate of IGMS in secondary and tertiary hospitals in Jiangsu is approximately 48.7%, with a higher rate in Southern Jiangsu. Endocrinology departments have the highest rate of IGMS usage. Medical staff are satisfied with the use of IGMS, and put forward higher expectations for the stability of networking and the standardization of training."

Background: N6‐methyladenosine (m6A) modification is essential for modulating RNA processing as well as expression, particularly in the context of malignant tumour progression. However, the exploration of m6A modification in nasopharyngeal carcinoma (NPC) remains very limited. Methods: RNA m6A levels were analysed in NPC using m6A dot blot assay. The expression level of methyltransferase‐like 14 (METTL14) within NPC tissues was analysed from public databases as well as RT‐qPCR and immunohistochemistry. The influences on METTL14 expression on NPC proliferation and metastasis were explored via in vitro as well as in vivo functional assays. Targeted genes of METTL14 were screened using the m6A and gene expression profiling microarray data. Actinomycin D treatment and polysome analysis were used to detect the half‐life and translational efficiency of ANKRD22. Flow cytometry, immunofluorescence and immunoprecipitation were used to validate the role of ANKRD22 on lipid metabolism in NPC cells. ChIP‐qPCR analysis of H3K27AC signalling near the promoters of METTL14, GINS3, POLE2, PLEK2 and FERMT1 genes. Results: We revealed METTL14, in NPC, correlating with poor patient prognosis. In vitro and in vivo assays indicated METTL14 actively promoted NPC cells proliferation and metastasis. METTL14 catalysed m6A modification on ANKRD22 messenger ribonucleic acid (mRNA), recognized by the reader IGF2BP2, leading to increased mRNA stability and higher translational efficiency. Moreover, ANKRD22, a metabolism‐related protein on mitochondria, interacted with SLC25A1 to enhance citrate transport, elevating intracellular acetyl‐CoA content. This dual impact of ANKRD22 promoted lipid metabolism reprogramming and cellular lipid synthesis while upregulating the expression of genes associated with the cell cycle (GINS3 and POLE2) and the cytoskeleton (PLEK2 and FERMT1) through heightened epigenetic histone acetylation levels in the nucleus. Intriguingly, our findings highlighted elevated ANKRD22‐mediated histone H3 lysine 27 acetylation (H3K27AC) signals near the METTL14 promoter, which contributes to a positive feedback loop perpetuating malignant progression in NPC. Conclusions: The identified METTL14‐ANKRD22‐SLC25A1 axis emerges as a promising therapeutic target for NPC, and also these molecules may serve as novel diagnostic biomarkers. [ABSTRACT FROM AUTHOR]

Single cell RNA sequencing (scRNA‐seq) provides a great convenience for studying tumor occurrence and development for its ability to study gene expression at the individual cell level. However, patient‐derived tumor tissues are composed of multiple types of cells including tumor cells and adjacent non‐malignant cells such as stromal cells and immune cells. The spatial locations of various cells in situ tissues plays a pivotal role in the occurrence and development of tumors, which cannot be elucidated by scRNA‐seq alone. Spatially resolved transcriptomics (SRT) technology emerges timely to explore the unrecognized relationship between the spatial background of a particular cell and its functions, and is increasingly used in cancer research. This review provides a systematic overview of the SRT technologies that are developed, in particular the more widely used cutting‐edge SRT technologies based on next‐generation sequencing (NGS). In addition, the main achievements by SRT technologies in precisely unveiling the underappreciated spatial locations on gene expression and cell function with unprecedented high‐resolution in cancer research are emphasized, with the aim of developing more effective clinical therapeutics oriented to a deeper understanding of the interaction between tumor cells and surrounding non‐malignant cells. [ABSTRACT FROM AUTHOR]